A Phase II Study of ZD6474 Alone and With Chemotherapy in Advanced NSCLC [non-small cell lung cancer]
Phase of Trial: Phase II
Latest Information Update: 06 Sep 2016
At a glance
- Drugs Vandetanib (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors AstraZeneca
- 30 Nov 2009 Pharmacodynamic outcomes, with respect to biomarker levels, reported in the Journal of Clinical Oncology.
- 28 Oct 2008 Results published early online in the Journal of Clinical Oncology.
- 20 Oct 2008 Primary endpoint 'Progression free survival' has been met at the predefined one-sided significant level of p<0.20.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History